10/12/2010

Alexza Pharmaceuticals has received a complete-response letter from the FDA for AZ-004, an inhaled treatment for agitation caused by schizophrenia or bipolar disorder. The agency voiced concern about clinical data showing that the drug causes respiratory side effects.

Full Story:
Reuters

Related Summaries